Recent patents on biotechnology最新文献

Background: Levothyroxine Sodium is a thyroid hormone replacement therapy for Hypothyroidism. Levothyroxine Sodium is approved to treat Hypothyroidisim, to suppress thyroid hormone release from cancerous thyroid nodules, and to prevent the growth of goiters. In addition, it is also used to treat conditions such as myxedema, cretinism, and obesity.

Objective: This assessment highlights the overview of the recent patents of Levothyroxine Sodium. This review includes patents grouped in sections like product patents, process patents, and composition-related patents, along with the treatment methodology. The objective of this article is to impel pseudoscientists to all existing patents in a solitary place.

Methods: Data were gathered from various internet-based resources, including Patentscope ® (WIPO), Worldwide Espacenet® (EPO), Google Patents, and InPASS (Indian patent database).

Results: Several new processes and composition-related patents of Levothyroxine Sodium have been reported. Further, due to the problem of photosensitivity, oxidation during development, and stability of Levothyroxine Sodium formulation, several excipients are tried in these patents to stabilize the same. However, the formulation of Levothyroxine Sodium with better characteristics needs to be developed.

Conclusion: Extensive exposure has been carried out towards various processes for the preparation of Levothyroxine Sodium and the composition of the same. This sort of dynamic exploration will clear the path for many generic players, which will lead to the reduction of the expense of the composition and accordingly enhance global health care at a less expensive cost.

Different compounds with bioactive constituents can be applied as biostimulants to increase plant growth and development under both normal and stressful conditions. Biostimulant utilization can be considered a sustainable and beneficial nutritional crop management, and may decrease the negative impacts of excessive chemical fertilization. Google scholar, Science Direct, CAB Direct, Springer Link, Scopus, Web of Science, Taylor and Francis, and Wiley Online Library have been checked. The search was done to all manuscript sections according to the terms "Glomus intraradices", "Trichoderma atroviride", "Trichoderma reesei", "Heteroconium chaetospira", "Arthrobacter spp.", "Acintobacter spp.", "Enterobacer spp.", "Pseudomonas spp.", "Ochrobactrum spp.", "Bacilus spp.", "Rhodococcus spp.", "Biostimulants", and "Plant growth promotion". On the basis of the initial check, Titles and Abstracts were reviewed based on online literature, and then articles were read carefully. Within the framework of sustainable crop management, this review article aimed to provide an overview of the application of the most common fungi and bacteria as plant biostimulants on various crops.

Despite an ever-increasing need for newer, safer, more effective, and more affordable therapies to treat a multitude of diseases and conditions, drug development takes too long, costs too much, and is too uncertain to be undertaken without the conferment of exclusionary rights or entry barriers to motivate and sustain investment in it. These entry barriers take the form of patents that protect intellectual property and marketing exclusivity provisions that are provided by statute. This review focuses on the basic ins and outs of regulatory and patent exclusivities for which new chemical entities (NCEs), referring to never-before approved drugs with an entirely new active ingredient, are eligible and uses RRx-001, a small molecule aerospace-derived NCE in development for the treatment of cancer, radiation toxicity, and diseases of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, as a "real world" example. This is intended as a '101-type' of primer; its aim is to help developers of original pharmaceuticals navigate the maze of patents, other IP regulations, and statutory exclusivities in major markets so that they can make proper use of them.

Proteases that perform keratin hydrolysis (keratinases) have great potential in biotechnology. After investigation, the next step to an industrial application is protecting intellectual property by patenting. There are many fields of discovered keratinase implementation dictated by features of the molecule and its producer. This article provides an overview of existing patents on keratinases. Among the patents found using terms related to 'keratinase', only those that contain data on the structure and features of the enzyme to provide a sufficient overview of the current situation are covered. It includes information on publication timelines of patents, as well as their origin; features of cultivation process and producers, such as fermentation type and pathogenicity; and features of enzymes, such as their classes, pH, and temperature optima. This article summarizes information about proprietary keratinases and reflects trends and dependencies in their production and application development. It is also the first review of existing patents on keratinases, which emphasizes the uniqueness and novelty of this article.

Background: Insulin-like growth factor-1 (IGF-1) is structurally similar to insulin and acts as an endocrine hormone secreted by the liver.

Objective: Production of recombinant human IGF-1 (rhIGF-1) in Escherichia coli (E.coli) and evaluation of its proliferation stimulatory activity.

Methods: hIGF-1 gene cloned into pBSK (+) simple vector was transformed into TOP 10 chemically competent cells of E. coli. Polymerase chain reaction (PCR) was achieved using specific hIGF-1 gene primers to confirm the successful transformation. To express the rhIGF-1 in E. coli (Rosetta (DE3) pLysS); the hIGF-1 gene was cloned into the pET-15b expression vector and then the recombinant pET-15b/IGF-1 vector was transformed into a chemically prepared competent expression bacterial cells; Rosetta (DE3) pLysS. The rhIGF-1 was expressed as insoluble aggregates called inclusion bodies (IBs) using a 2 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) inducer. IBs were solubilized in a denatured form using 6 M guanidinium hydrochloride (GdmCl), followed by in vitro protein refolding using the rapid dilution method. The refolded hIGF-1 was purified using the HiTrap- ANX anion exchange column. Western blot and ELISA using rabbit polyvalent anti-hIGF- 1 were performed to confirm the protein antigenic identity. Cell proliferation activity of rhIGF-1 was testified on normal human lung cell line (WI-38).

Results: rhIGF-1 was purified from the HiTrap-ANX column at a concentration of 300 μg/ml. Western blot showed a single 7.6 kDa band obtained in the induced Rosetta (DE3) pLYsS. ELISA confirmed the molecular identity of the rhIGF-1 epitope, the concentration of purified rhIGF-1 obtained from the ELISA standard curve using rhIGF-1 reference protein as a standard was 300 μg/ml, and activity on WI-38 cells was 2604.17I U/mg.

Conclusion: Biologically active native rhIGF-1 protein was successfully expressed. Patents related to the preparation of IGF-1 were mentioned along the text.

Type 2 diabetes (T2D), which affects many people around the world, is one of the diseases that is on the rise. Various studies have revealed that insulin resistance and lessened insulin production have been associated with T2D, and they also show that this disease can have a genetic origin and is associated with different genes, such as KCNQ1, PPAR-γ, calpain-10, ADIPOR2, TCF7L2, which can be utilized as therapeutic targets. Different therapeutic approaches and strategies such as exercise and diet, pharmacological approaches, and utilization of nanoparticles in drug delivery and gene therapy can be effective in the treatment and control of T2D. Glucagon-like peptide 1 (GLP-1) and sodiumglucose cotransporter-2 (SGLT2) have both been considered as drug classes in the treatment of T2D and T2D-related diseases such as cardiovascular disease and renal disease, and have considerable influences such as diminished cardiovascular mortality in individuals with T2D, ameliorated postprandial glycaemia, ameliorated fasting glycaemia, and diminished bodyweight on disease treatment and improvement process. In the present review article, we have attempted to explore the risk factors, genes, and diseases associated with T2D, therapeutic approaches in T2D, the influences of drugs such as dapagliflozin, metformin, acarbose, Januvia (sitagliptin), and ertugliflozin on T2D in clinical trials and animal model studies. Research in clinical trials has promising results that support the role of these drug approaches in T2D prophylaxis and ameliorate safety even though additional clinical research is still obligatory.

Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore,the article has been withdrawn.

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found athttps://benthamscience.com/editorial-policies-main.php.

Bentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published andwill not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structureor table that has been published elsewhere must be reported, and copyright permission for reproductionmust be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authorsagree that the publishers have the legal right to take appropriate action against the authors, if plagiarism orfabricated information is discovered. By submitting a manuscript the authors agree that the copyright oftheir article is transferred to the publishers if and when the article is accepted for publication.